Drug intelligence / Profile preview

iodine-131-aGPC3-Scfv

Development stage: Phase 1
Lead developer: Department of Nuclear Medicine
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Iodine-131-aGPC3-Scfv is a radiopharmaceutical composed of the radioisotope Iodine-131 conjugated to an anti-Glypican-3 (GPC3) single-chain variable fragment (scFv) antibody. This construct is designed to specifically target GPC3, a protein highly overexpressed in hepatocellular carcinoma (HCC) cells, but not in normal liver tissue. It is being developed for radio-immunoimaging to diagnose HCC and has potential for radio-immunotherapy by delivering localized radiation to cancer cells.

Other names: 131I-scFvanti-GPC3 scFv antibodyanti-GPC-3 scFv antibodyanti-GPC 3 scFv antibody

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on iodine-131-aGPC3-Scfv.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iodine-131-aGPC3-Scfv.

Explore the full profile